N Bansback

Summary

Affiliation: University of Sheffield
Country: UK

Publications

  1. ncbi Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK
    A Brennan
    Operational Research, School of Health and Related Research, University of Sheffield, Sheffield, South Yorkshire, UK
    Rheumatology (Oxford) 43:62-72. 2004
  2. ncbi Using contrast sensitivity to estimate the cost-effectiveness of verteporfin in patients with predominantly classic age-related macular degeneration
    N Bansback
    Health Economics and Decision Science, ScHARR School of Health and Related Research, University of Sheffield, Sheffield, UK
    Eye (Lond) 21:1455-63. 2007
  3. ncbi Economic evaluation of gemcitabine in the treatment of pancreatic cancer in the UK. How important is quality of life?
    Nick Bansback
    ScHARR Technology Assessment Group, School of Health and Related Research, University of Sheffield, Regent Court, 40 Regent Street, S1 4DA Sheffield, UK
    Eur J Health Econ 5:188-9. 2004
  4. pmc Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden
    N J Bansback
    Health Economics and Decision Science, ScHARR, University of Sheffield, Regent Court, 40 Regent Street, Sheffield S1 4DA UK
    Ann Rheum Dis 64:995-1002. 2005
  5. ncbi Estimating the cost and health status consequences of treatment with TNF antagonists in patients with psoriatic arthritis
    N J Bansback
    Health Economics and Decision Science, School of Health and Related Research ScHARR, University of Sheffield, Regent Court, 40 Regent Street, Sheffield S1 4DA, UK
    Rheumatology (Oxford) 45:1029-38. 2006
  6. ncbi Determinants of health related quality of life and health state utility in patients with age related macular degeneration: the association of contrast sensitivity and visual acuity
    N Bansback
    Health Economics and Decision Science, ScHARR School of Health and Related Research, The University of Sheffield, Regent Court, 30 Regent Street, Sheffield, S1 4DA, UK
    Qual Life Res 16:533-43. 2007
  7. ncbi Modelling the cost effectiveness of TNF-alpha antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry
    A Brennan
    Health Economics and Decision Science, School of Health and Related Research ScHARR, The University of Sheffield, UK
    Rheumatology (Oxford) 46:1345-54. 2007
  8. ncbi A preliminary model-based assessment of the cost-utility of a screening programme for early age-related macular degeneration
    J Karnon
    School of Health and Related Research, University of Sheffield, UK
    Health Technol Assess 12:iii-iv, ix-124. 2008
  9. doi Biologic drugs for rheumatoid arthritis in the Medicare program: a cost-effectiveness analysis
    Allan J Wailoo
    Health Economics and Decision Science, ScHARR, University of Sheffield, Sheffield, UK
    Arthritis Rheum 58:939-46. 2008
  10. doi Infliximab, etanercept and adalimumab for the treatment of ankylosing spondylitis: cost-effectiveness evidence and NICE guidance
    Allan Wailoo
    Rheumatology (Oxford) 47:119-20. 2008

Detail Information

Publications16

  1. ncbi Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK
    A Brennan
    Operational Research, School of Health and Related Research, University of Sheffield, Sheffield, South Yorkshire, UK
    Rheumatology (Oxford) 43:62-72. 2004
    ..e. adults previously failing two disease-modifying anti-rheumatic drugs (DMARDs). It compares a DMARD sequence with etanercept third line against the same sequence excluding etanercept...
  2. ncbi Using contrast sensitivity to estimate the cost-effectiveness of verteporfin in patients with predominantly classic age-related macular degeneration
    N Bansback
    Health Economics and Decision Science, ScHARR School of Health and Related Research, University of Sheffield, Sheffield, UK
    Eye (Lond) 21:1455-63. 2007
    ....
  3. ncbi Economic evaluation of gemcitabine in the treatment of pancreatic cancer in the UK. How important is quality of life?
    Nick Bansback
    ScHARR Technology Assessment Group, School of Health and Related Research, University of Sheffield, Regent Court, 40 Regent Street, S1 4DA Sheffield, UK
    Eur J Health Econ 5:188-9. 2004
  4. pmc Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden
    N J Bansback
    Health Economics and Decision Science, ScHARR, University of Sheffield, Regent Court, 40 Regent Street, Sheffield S1 4DA UK
    Ann Rheum Dis 64:995-1002. 2005
    ..Societal decision makers increasingly emphasise their need for evidence based economic analyses to make reimbursement decisions...
  5. ncbi Estimating the cost and health status consequences of treatment with TNF antagonists in patients with psoriatic arthritis
    N J Bansback
    Health Economics and Decision Science, School of Health and Related Research ScHARR, University of Sheffield, Regent Court, 40 Regent Street, Sheffield S1 4DA, UK
    Rheumatology (Oxford) 45:1029-38. 2006
    ..We estimate the long-term impact on health status of prescribing the TNF antagonist etanercept, and evaluate the cost-effectiveness in a health economic model...
  6. ncbi Determinants of health related quality of life and health state utility in patients with age related macular degeneration: the association of contrast sensitivity and visual acuity
    N Bansback
    Health Economics and Decision Science, ScHARR School of Health and Related Research, The University of Sheffield, Regent Court, 30 Regent Street, Sheffield, S1 4DA, UK
    Qual Life Res 16:533-43. 2007
    ..We designed a study to examine whether the contribution of contrast sensitivity in explaining HRQoL and health utilities over and above that of visual acuity...
  7. ncbi Modelling the cost effectiveness of TNF-alpha antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry
    A Brennan
    Health Economics and Decision Science, School of Health and Related Research ScHARR, The University of Sheffield, UK
    Rheumatology (Oxford) 46:1345-54. 2007
    ..To evaluate the cost effectiveness of TNF-alpha antagonist therapies for rheumatoid arthritis (RA) in the United Kingdom using data from the British Society for Rheumatology Biologics Registry (BSRBR)...
  8. ncbi A preliminary model-based assessment of the cost-utility of a screening programme for early age-related macular degeneration
    J Karnon
    School of Health and Related Research, University of Sheffield, UK
    Health Technol Assess 12:iii-iv, ix-124. 2008
    ..A further objective was to identify the major areas of uncertainty in the model, and so inform future research priorities in this disease area...
  9. doi Biologic drugs for rheumatoid arthritis in the Medicare program: a cost-effectiveness analysis
    Allan J Wailoo
    Health Economics and Decision Science, ScHARR, University of Sheffield, Sheffield, UK
    Arthritis Rheum 58:939-46. 2008
    ..We undertook to develop a model to compare the costs and quality-adjusted life years (QALYs) generated by each of the 4 biologic agents...
  10. doi Infliximab, etanercept and adalimumab for the treatment of ankylosing spondylitis: cost-effectiveness evidence and NICE guidance
    Allan Wailoo
    Rheumatology (Oxford) 47:119-20. 2008
  11. ncbi Using the health assessment questionnaire to estimate preference-based single indices in patients with rheumatoid arthritis
    Nick Bansback
    St Paul s Hospital, Vancouver, British Columbia, Canada
    Arthritis Rheum 57:963-71. 2007
    ....
  12. doi Health state utility values: a description of their development and application for rheumatic diseases
    Nick Bansback
    Centre for Health Evaluation and Outcome Sciences, Vancouver, British Columbia, Canada
    Arthritis Rheum 59:1018-26. 2008
  13. ncbi Cost-effectiveness of surgery plus radiotherapy versus radiotherapy alone for metastatic epidural spinal cord compression
    Kenneth C Thomas
    Department of Surgery Orthopedics, University of Calgary, Calgary, AB, Canada
    Int J Radiat Oncol Biol Phys 66:1212-8. 2006
    ..The current study compared the cost-effectiveness of the two approaches...
  14. ncbi Economic evaluations in rheumatoid arthritis: a critical review of measures used to define health States
    Nick Bansback
    Centre for Health Evaluation and Outcome Sciences, St Paul s Hospital, Vancouver, British Columbia, Canada
    Pharmacoeconomics 26:395-408. 2008
    ..Further research is also required to explore the advantages in using either continuous or discrete health states...
  15. ncbi A prognostic model for functional outcome in early rheumatoid arthritis
    Nick Bansback
    Early Rheumatoid Arthritis Study Group, ERAS, Department of Rheumatology, City Hospital, St Albans, UK
    J Rheumatol 33:1503-10. 2006
    ..To construct a prognostic algorithm to predict 5-year functional outcome in rheumatoid arthritis (RA), based on the Health Assessment Questionnaire (HAQ)...
  16. ncbi Considerations and preliminary proposals for defining a reference case for economic evaluations in ankylosing spondylitis
    Nick Bansback
    Centre for Health Evaluation and Outcome Sciences, St Paul s Hospital, Vancouver, British Columbia, Canada
    J Rheumatol 34:1178-83. 2007
    ..Ten methodological issues are presented that will be important for future development of evaluations. Tentative proposals to define the issues in a reference case for AS are made, along with recommendations for further research...